

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 86050

Title: Toxicity of targeted anticancer treatments on the liver in myeloproliferative

neoplasms

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05199192 Position: Peer Reviewer Academic degree: MD

Professional title: Deputy Director

Reviewer's Country/Territory: China

Author's Country/Territory: Romania

Manuscript submission date: 2023-05-28

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-06-18 11:37

Reviewer performed review: 2023-06-28 17:28

Review time: 10 Days and 5 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No creativity or innovation



https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

1. This manuscript describes the hepatotoxicity of targeted therapy of myeloproliferative neoplasms (MPN) from the aspects of mechanism, treatment and prevention, which has practical clinical significance. However, the main content discusses the hepatotoxicity of targeted therapy of chronic myeloid leukemia (CML), which is only a classification of MPN. The title is inappropriate. 2. The page 7 of the manuscript states that "Normalization of liver enzymes' values after discontinuation of the drug supports the diagnosis of DILI", which is a crude exclusion method. It is important to highlight the necessity of liver biopsy and genetic testing for hereditary diseases, as and when 3. This manuscript describes that the hepatotoxicity of MPN targeted drugs may be related to aspects such as oxidative stress, bile acid metabolism, and immunity, and further elaborating on its related mechanisms may be better. 4. If the importance of supplementing the assessment of pre-liver compensatory function in targeted therapy could be added, the manuscript may be more readable. 5. On page 8 of the manuscript, it is mentioned to use a novel score-based method to evaluate the dressing change standard. It would be better if the specific scoring criteria could be further elucidated. 6.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

The conclusion section of the manuscript points out that minor liver injury can be overcome with drug discontinuation and/or dose reductions. This could potentially impact the treatment of primary diseases. It is worth noting the use of hepatoprotective drugs in such cases. 7. If the author could further focus on the overview, diagnosis, management, and prevention of DILI, and supplement its clinical classification and prognosis, the manuscript may be better.



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 86050

Title: Toxicity of targeted anticancer treatments on the liver in myeloproliferative

neoplasms

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05224683 Position: Peer Reviewer Academic degree: DSc, MSc

Professional title: Postdoc, Postdoctoral Fellow, Research Scientist, Senior Scientist

Reviewer's Country/Territory: Bangladesh

Author's Country/Territory: Romania

Manuscript submission date: 2023-05-28

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-07-04 08:05

Reviewer performed review: 2023-07-04 08:24

Review time: 1 Hour

	[Y] Grade A: Excellent [] Grade B: Very good [] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No creativity or innovation
r	[]



Scientific significance of the conclusion in this manuscript	[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Very informative review



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 86050

Title: Toxicity of targeted anticancer treatments on the liver in myeloproliferative

neoplasms

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02451447 Position: Editorial Board Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: United States

Author's Country/Territory: Romania

Manuscript submission date: 2023-05-28

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-07-16 14:36

Reviewer performed review: 2023-07-16 14:59

Review time: 1 Hour

[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Good
[] Grade D: Fair [] Grade E: Do not publish
[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
[] Grade D: No creativity or innovation



Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This authors reviewed the hepatotoxicity of targeted therapy in myeloproliferative neoplasms. Comments: 1. For "abstract": Please remove "slightly" in the sentence "Because of its central role in metabolism, the liver is slightly susceptible to the damaging effects....." 2. Please complete this sentence with reference x: "...explaining the wide range of phenotypic traits in terms of clinical presentation and severity (x)." 3.

Please format the reference in same format, especially the paragraph of "Drug induced liver injury (DILI): brief overview." 4. For "Risk factors for DILI", please give more detailed information of each risk factors, such as why PPI use is a risk factor? 5.

For the "Diagnosis of DILI", the authors should discuss patterns of liver injury, such as hepatitic or cholestatic patterns. Any pathologic changes in biopsy specimens? 6. The authors need to discuss outcomes of these liver injuries.